Construction and validation of the Oxford Neurodevelopment Assessment (OX-NDA) in 1-year-old Brazilian children

Michelle Fernandes1,2,3, Diego Bassani4,5, Elaine Albernaz6

  • 1MRC Lifecourse Epidemiology Centre and Human Development & Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK. m.c.fernandes@soton.ac.uk.

BMC Pediatrics
|December 23, 2022
PubMed

Insights

The Oxford Neurodevelopment Assessment (OX-NDA) shows moderate agreement with the Bayley Scales of Infant Development III (BSID-III) for identifying infants at risk of cognitive and motor delays. This rapid, low-cost tool is suitable for low- and middle-income countries.

Area of Science:

  • Global child development
  • Pediatric neurodevelopmental assessment
  • Low- and middle-income country (LMIC) health interventions

Background:

  • Over 250 million children globally face developmental delay risk before age five.
  • Early identification and intervention in the first two years are crucial for lasting positive effects.
  • Limited availability of infant development assessments for LMIC settings poses a significant challenge.

Purpose of the Study:

  • To introduce the Oxford Neurodevelopment Assessment (OX-NDA), a novel tool for assessing 1-year-old children.
  • To evaluate the OX-NDA's performance against the established Bayley Scales of Infant Development III (BSID-III).
  • To determine the psychometric properties of the OX-NDA for use in LMIC contexts.

Main Methods:

  • The OX-NDA was developed considering 16 international infant development tools.
  • Agreement with BSID-III was assessed using intra-class correlations, Bland-Altman analyses, and sensitivity/specificity in 104 Brazilian infants.
  • Reliability was evaluated using Cohen's kappas (inter-rater) and Cronbach's alphas (internal consistency).

Main Results:

  • Moderate agreement (ICC 0.63-0.68) was found for cognitive and motor outcomes between OX-NDA and BSID-III.
  • Low agreement (ICC 0.30) was observed for language outcomes.
  • The OX-NDA demonstrated high inter-rater and test-retest reliability and required less than 20 minutes for administration.

Conclusions:

  • The OX-NDA offers moderate accuracy for identifying infants at risk of cognitive and motor delays, with lower accuracy for language delays.
  • It is a rapid, cost-effective assessment designed for LMIC populations.
  • Further research is recommended to validate the OX-NDA across diverse populations and for language delay identification in Brazil.
Abstract

Related Concept Videos